3-MMC

Illegal as a positional isomer of the controlled substance mephedrone. Explicitly designated as a controlled substance on December 13, 2023, and categorized by the DEA as a Schedule I positional isomer.⁴¹

3-MMC is named in Australia's Customs (Prohibited Imports) Regulations 1956. The regulations prohibit its importation except as permitted by the regulatory scheme.

Annex V.2 provides for controlled/narcotic-equivalent treatment; whether this applies to every activity depends on the applicable Suchtmittelgesetz provisions.

3-MMC is a controlled psychotropic substance in Belgium under Annex IIb of the Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances. Since 17 March 2023, its import, export, transport, manufacture, production, possession, sale, supply, delivery, and acquisition require prior authorization; authorization is limited to scientific or medical purposes. Contraventions are punishable under Article 2bis of the Law of 24 February 1921.

The current ANVISA list places 3-MMC in F2.

The Ministry of Public Security measure took effect on 1 October 2015.

Banned substance under national drug control legislation.

3-MMC is listed as 3-Methylmethcathinon on Liste B of Denmark's Executive Order on Euphoriant Substances. Liste B substances may be used only for medical and scientific purposes. Receipt and possession are limited to the persons, institutions, pharmacies, laboratories, and businesses authorized under the Order; import, export, manufacture, preparation, and trade are likewise regulated by authorization requirements.

3-MMC (3-Methylmethcathinon) is listed in Anlage I to Germany's Betäubungsmittelgesetz as 2-(Methylamino)-1-(3-methylphenyl)propan-1-on. Anlage I contains non-marketable narcotics, for which the Federal Institute for Drugs and Medical Devices may grant authorization only exceptionally for scientific or other public-interest purposes. Unauthorized manufacture, trade, import, export, sale, acquisition, or possession without the required written acquisition authorization is punishable by up to five years' imprisonment or a fine.

The 8 February 2024 Gazette directly inserted 3-Methylmethcathinone into the Schedule of psychotropic substances under serial 110ZZE. Section 2(xxiii) defines a psychotropic substance by inclusion in the Schedule (including a substance, natural material, salt or preparation), while section 3 provides the Central Government's notification mechanism to add or omit scheduled substances; the NDPS Act contains no general structural-analogue rule. Accordingly, 3-MMC's Indian control is direct listing, not automatic analogue coverage. Section 8(c) prohibits producing, manufacturing, possessing, selling, purchasing, transporting, warehousing, using, consuming, importing/exporting and transhipping a narcotic drug or psychotropic substance except for medical or scientific purposes and as authorized by the Act, rules, orders, licence, permit or authorization. For a psychotropic substance, section 22 provides: small quantity—rigorous imprisonment up to one year or fine up to ₹10,000 or both; greater than small but less than commercial—rigorous imprisonment up to ten years and fine up to ₹1 lakh; commercial quantity—rigorous imprisonment 10–20 years and fine ₹1–2 lakh, with a court permitted to exceed ₹2 lakh for recorded reasons. The official 16 April 2025 S.O. 1730(E) inserted new entries after 110ZZE, and the official 18 February 2026 S.O. 906(E) inserted later entries after 110ZZI while listing the prior amendments through 2025; neither removes 110ZZE. The CBN official substances page also identifies its psychotropic list as the NDPS Act 1985 (2025 Edition) and its quantity list as updated by S.O. 907(E) dated 18 February 2026.

Initially classified as a List II (soft drug) substance effective October 28, 2021.³⁶ Subsequently reclassified to List I (hard drug) in April 2024,³⁵ carrying more severe penalties for possession and distribution.

3-MMC is listed in Norway's narcotics regulation as 3-metylmetkatinon. The regulation's prohibition applies to listed narcotic substances.

Classified as a II-P category controlled substance since April 25, 2024, making possession, production, and distribution illegal.

3-MMC (3-methylmethcathinone) is covered in Schedule 2 Part III as a homologue of the listed substance methcathinone. Part III covers chemically related substances that incorporate a structural fragment similar to a listed substance or have similar pharmacodynamic properties, unless separately listed elsewhere in Schedule 2. The Act prohibits possession, use, and dealing in Part III drugs except in the statutory medicinal and authorised-professional circumstances; contraventions are offences. The current Schedule 2, including this homologue provision, was substituted with effect from 14 December 2022.

Classified as a narcotic substance under Swedish drug control legislation.

The official EGM/TUBIM 2014 report identifies 2013/5742 as the decision that subjected 113 new psychoactive substances to the 2313 law and its Appendix 2 expressly lists '3-MMC ... 1-(3-methylphenyl)-2-(methylamino)propane-1-one.' The current EGM/Narcotics 2025 report describes Turkey's EWS process: newly encountered or risk-identified NPS are assessed and, where appropriate, brought under 2313; generic classification has operated since 2015 and 1,078 NPS had been included from 2008 through 31 July 2025, including 205 synthetic cathinones. This framework can capture structurally defined derivatives, but 3-MMC is controlled by its explicit listing; that listing does not establish that every analogue is automatically controlled absent a generic-class entry. The Justice Ministry's current TCK compilation states that article 188(1) carries 20–30 years' imprisonment and 2,000–20,000 day judicial fine for unauthorized manufacture/import/export, article 188(3) carries at least 10 years and 1,000–20,000 day fine for domestic sale, offering, giving, dispatch, transport, storage, purchase, acceptance or possession, and article 188(4)(a) raises the penalty by one-half where the substance is a synthetic cathinone or derivative. Article 191(1) carries 2–5 years for use or possession for use; article 191 provides a five-year deferment of public prosecution, at least one year of probation (extendable by up to two years) and testing at least twice yearly. The 2025 official TCK compilation retains the synthetic-cathinone language added by 7445 (2023), and the 2025 EGM report records the NPS-control framework and 2024 operations. The 2013/5742 listing of 3-MMC remains in effect.

Controlled as a Class B substance under the Misuse of Drugs Act 1971 through the cathinone catch-all clause, which covers structurally related compounds.

Swissmedic expressly says the list is not legally exhaustive and that binding schedules are the BetmVV-EDI annexes; the agency currently identifies 3-MMC as part of the cathinone group.